Text Size

Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors

This study has been completed.
Sponsor:
Collaborator:
Thrasher Research Fund
Information provided by (Responsible Party):
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT00907244
First received: May 20, 2009
Last updated: October 26, 2012
Last verified: January 2012
History of Changes
  Purpose

The purpose of this study is to get information regarding the usefulness and accuracy of this new magnetic resonance imaging (MRI) technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors.


Condition
Brain Tumors

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: CHP-901:Arterial Spin Labeling Perfusion MR Imaging in Pediatric Brain Tumors

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Children's Hospital of Philadelphia:

Enrollment: 13
Study Start Date: April 2008
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to get information regarding the usefulness and accuracy of this new MRI technique - termed arterial spin labeling (ASL) - in the diagnosis of pediatric brain tumors. This technique can non-invasively measure the blood flow to the brain during MRI examination. Because aggressive brain tumors require new blood vessels and a high level of blood supply to support its growth, we believe the tumor blood flow measured using ASL is a reliable indicator of tumor grade. This information may be useful for doctors to make treatment decisions and to monitor patients' response to treatment.

  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients between 0-18 years who are diagnosed with primary brain tumor, undergoing MRI for clinical purpose are eligible for the study.

Criteria

Inclusion Criteria:

  • Age 0-18 years
  • Primary brain tumor (newly diagnosed or recurrent) with measurable disease (at least 1cm2)

Exclusion Criteria:

  • Patients with cardiac pacemaker or ferrous metal foreign bodies
  • Patients with medical problems contradictive to receiving MRI scans.
  • Patients requiring general anesthesia or sedation for their MRI scan.
  • Patients with a history of cerebrovascular disorders (stroke, moya moya) that may alter cerebral perfusion.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00907244

Locations
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Children's Hospital of Philadelphia
Thrasher Research Fund
Investigators
Principal Investigator: Michael Fisher, M.D. Children's Hospital of Philadelphia
  More Information

No publications provided

Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT00907244     History of Changes
Other Study ID Numbers: CHP 901 ASL, 2008-4-5917
Study First Received: May 20, 2009
Last Updated: October 26, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
 Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 16, 2013